AUGUST SEMINAR NOTICE

Presented by
Yale School of Medicine's, Department of Therapeutic Radiology

"Imaging-Based Biomarkers for Brain Metastases"
1. Enoch Chang, Medical Student
Yale School of Medicine

"Oligometastatic Disease and Biologically Guided Radiation Therapy (BGRT)"
2. James B. Yu, MD, MHS
Professor of Therapeutic Radiology; Medical Director, Smilow Radiation Oncology; Director, Prostate & Genitourinary Cancer Radiotherapy Program

Date: Thursday, August 6, 2020, 9:00AM
Location: Zoom Meeting

Course Director/Host: Henry S. Park, MD, MPH
There is no corporate support for this activity
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending Physicians; Housestaff/Fellows; Medical Students; Nurses; PA's; Other

NEEDS ASSESSMENT
1. To understand the role of quantitative imaging biomarkers in clinical oncology. Learn about applications of machine learning methods in cancer research. Appreciate the value of deep learning survival models for improving prognostication.
2. Radiation Oncologists need to learn about emerging clinical paradigm of oligometastatic disease[1]. Aggressive local therapy with radiotherapy has been shown to be beneficial for patients with oligometastatic disease. Radiosurgery plays an important role in aggressive local therapy. Combining radiosurgery with PET based tumor tracking may allow for efficient therapy and expansion of the role of stereotactic ablative treatment for metastatic disease. ([1]Yu JB, Brock KK, Campbell AM et al. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. IJROBP. 2020. [2]Lievens Y, et al. Defining oligometastatic disease from radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020.)

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. To understand the utility of quantitative imaging biomarkers for classification and risk stratification in patients with cancer. To assess machine learning methods for improving cancer care. To evaluate deep learning survival models for improving brain metastasis prognostication.
2. Understand current consensus definition of oligometastatic disease. Understand the clinical evidence supporting stereotactic radiotherapy for oligometastatic disease. Understand the mechanics and potential of biologically guided radiation therapy.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
James B. Yu, MD, MHS – Augmenix/Boston Scientific-Honorarium/Speaking fees, Speaker/Consultant; Galera Pharmaceuticals- Honorarium, Advisory board; Enoch Chang, Med Student– None; Henry S. Park, MD, MPH – RadOncQuestions, LLC, Honorarium-Editor

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.